Shattuck Labs (NASDAQ:STTK) Given Buy Rating at Needham & Company LLC

Shattuck Labs (NASDAQ:STTK)‘s stock had its “buy” rating reaffirmed by stock analysts at Needham & Company LLC in a research report issued on Friday, Benzinga reports. They presently have a $12.00 target price on the stock. Needham & Company LLC’s price target would indicate a potential upside of 7.72% from the stock’s current price.

Separately, HC Wainwright reiterated a “buy” rating and set a $28.00 price target on shares of Shattuck Labs in a research note on Thursday.

Shattuck Labs Stock Up 0.4 %

Shares of NASDAQ STTK traded up $0.04 during trading on Friday, hitting $11.14. The company had a trading volume of 107,722 shares, compared to its average volume of 355,319. The stock has a fifty day simple moving average of $9.34 and a two-hundred day simple moving average of $6.85. Shattuck Labs has a fifty-two week low of $1.33 and a fifty-two week high of $11.62. The firm has a market capitalization of $529.71 million, a price-to-earnings ratio of -5.41 and a beta of 1.98.

Shattuck Labs (NASDAQ:STTK) last issued its earnings results on Thursday, May 2nd. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.08. The company had revenue of $1.15 million for the quarter, compared to the consensus estimate of $0.30 million. Shattuck Labs had a negative net margin of 5,268.44% and a negative return on equity of 63.08%. The firm’s revenue for the quarter was up 2200.0% compared to the same quarter last year. On average, analysts anticipate that Shattuck Labs will post -1.85 earnings per share for the current year.

Insider Buying and Selling at Shattuck Labs

In related news, insider Stephen Stout sold 16,004 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $10.53, for a total transaction of $168,522.12. Following the sale, the insider now owns 74,437 shares in the company, valued at $783,821.61. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 9.89% of the company’s stock.

Institutional Investors Weigh In On Shattuck Labs

Several institutional investors have recently bought and sold shares of STTK. Cannon Global Investment Management LLC acquired a new position in shares of Shattuck Labs during the first quarter worth $91,000. Tower Research Capital LLC TRC lifted its stake in Shattuck Labs by 79.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 13,553 shares of the company’s stock valued at $97,000 after buying an additional 5,989 shares in the last quarter. Reliant Investment Management LLC purchased a new stake in shares of Shattuck Labs in the fourth quarter worth approximately $143,000. SG Americas Securities LLC acquired a new position in Shattuck Labs in the fourth quarter worth approximately $268,000. Finally, Monashee Investment Management LLC acquired a new stake in shares of Shattuck Labs in the fourth quarter worth $713,000. 58.74% of the stock is currently owned by hedge funds and other institutional investors.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.